Methyloctatropine bromide
Brand names,
Methyloctatropine bromide
Analogs
Methyloctatropine bromide
Brand Names Mixture
Methyloctatropine bromide
Chemical_Formula
C17H32BrNO2
Methyloctatropine bromide
RX_link
No information avaliable
Methyloctatropine bromide
fda sheet
Methyloctatropine bromide
msds (material safety sheet)
Methyloctatropine bromide
Synthesis Reference
No information avaliable
Methyloctatropine bromide
Molecular Weight
362.346 g/mol
Methyloctatropine bromide
Melting Point
329 oC
Methyloctatropine bromide
H2O Solubility
1600 mg/L
Methyloctatropine bromide
State
Solid
Methyloctatropine bromide
LogP
0.60
Methyloctatropine bromide
Dosage Forms
Tablet (oral, 50mg)
Methyloctatropine bromide
Indication
For use in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying.
Methyloctatropine bromide
Pharmacology
Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion.
Methyloctatropine bromide
Absorption
Gastrointestinal absorption is poor and irregular. Total absorption after an oral dose is about 10 to 25%.
Methyloctatropine bromide
side effects and Toxicity
No information avaliable
Methyloctatropine bromide
Patient Information
Methyloctatropine bromide
Organisms Affected
Humans and other mammals